Prospective Clinical Study of Unilateral or Bilateral Implantation of Intraocular Lens in Cataract Patients

Sponsor
Peking University Third Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04265820
Collaborator
(none)
120
1
2
9.1
13.1

Study Details

Study Description

Brief Summary

This is to evaluate the satisfaction of patient and postoperative functional vision of unilateral or bilateral Implantation of intraocular lens(IOLs) in cataract patients.

Condition or Disease Intervention/Treatment Phase
  • Device: unilateral implantation of IOL
  • Device: bilateral implantation of IOL
N/A

Detailed Description

The subjects will undergo uneventful phacoemulsification and implantation of IOL.

The subjects will be divided into two groups . The unilateral cataract patients in the Group 1 will undergo unilateral surgery, and the bilateral cataract patients in the Group 2 will undergo bilateral surgery. IOL may be monofocal,bifocal ,or trifocal,according to the patients preference and the eyes condition. In each group, the subjects will be divided into three subgroups according to the type of the IOLs.Compare binocular functional vision and the satisfaction of patient between the two groups at postoperative 3 months.Compare binocular functional vision and the satisfaction of patient with different IOLs among the subgroups.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prospective Clinical Study of Unilateral or Bilateral Implantation of Intraocular Lens in Cataract Patients
Actual Study Start Date :
Oct 28, 2019
Anticipated Primary Completion Date :
May 1, 2020
Anticipated Study Completion Date :
Aug 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group 1

The unilateral cataract patients in the Group 1 will undergo phacoemulsification and unilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.

Device: unilateral implantation of IOL
unilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal,according to the patients preference and the eyes condition.

Active Comparator: Group 2

The bilateral cataract patients in the Group 2 will undergo phacoemulsification and bilateral implantation of IOLs.The subjects will be divided into three subgroups according to the type of the IOLs.

Device: bilateral implantation of IOL
bilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal,according to the patients preference and the eyes condition.

Outcome Measures

Primary Outcome Measures

  1. monocular and binocular visual acuity [3 months postoperatively]

    uncorrected distance visual acuity (UCVA), intermediate visual acuity, near visual acuity will be measured at 5m, 80cm and 40cm respectively. All visual acuity measurements will be conducted under photopic conditions (85 cd/m2) and at 100% contrast

Secondary Outcome Measures

  1. Binocular Contrast sensitivity [3 months postoperatively]

    Contrast sensitivity measures will be conducted binocularly, under photopic, mesopic (5 cd/m2), photopic with glare and mesopic with glare conditions, with the OPTEC 6500 contrast sensitivity test (Stereo Optical, USA). Contrast sensitivity will be evaluated at five spatial frequencies (1.5, 3, 6, 12, and 18 cycles per degree [cpd]). Patients will be allowed 5 minutes to adapt to each illumination level before testing.

  2. Binocular Defocus Curve [3 months postoperatively]

    Binocular defocus curves will be obtained in all patients, positioned at 5m under photopic (>85 cd/m 2 ) condition to measure the visual acuity with each defocus lens, representing the consecutive visual function of each eye. Negative lenses were added in 0.50 D steps and the visual acuity will be recorded for each type of defocus level. The procedure will be then repeated but with positive lenses. The range of defocus evaluated is from -4.00D to +2.00D.

  3. stereopsis [3 months postoperatively]

    Use block diagram of random-spot synoptophore to observe long distance stereopsis vision and yan's stereogram to observe short distance stereopsis vision.

  4. Fusion function [3 months postoperatively]

    The fusion function of perception and movement (convergence and divergence)will be examined with a synoptophore.

  5. Subjective visual quality [3 months postoperatively]

    Photic phenomena (score according to severity,0~4, higher scores mean worse)and spectacle dependence percentages will be evaluated by questionnaire.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with unilateral or bilateral age related cataracts

  • Regular corneal topography and Preoperative corneal astigmatism ≤ 0.75 Diopter

Exclusion Criteria:
  • Pregnant or nursing women

  • In the presence of other ocular diseases that may affect the stability of the lens capsule (pseudoexfoliation syndrome, glaucoma, traumatic cataract, Marfan syndrome, etc.)

  • Pupil abnormality (non-reactive pupil, tonic pupils, abnormally shaped pupils, etc.)

  • History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerv atrophy, amblyopia, strabismus, microphthalmos, aniridia, epiretinal membrane etc.) in the study eyes that could alter or limit final postoperative visual prognosis.

  • Patients with history of ocular trauma or prior ocular surgery including refractive procedures

  • postoperative visual acuity of worse than 0.2 logMAR in any eye

  • Patients using systemic or ocular medication that affect visual acuity.

  • Patients participating in other clinical trials during the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking University Third Hospital Beijing Beijing China 100191

Sponsors and Collaborators

  • Peking University Third Hospital

Investigators

  • Study Director: Qi Hong, PhD,MD, Peking University Third Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT04265820
Other Study ID Numbers:
  • 20191126
First Posted:
Feb 12, 2020
Last Update Posted:
Feb 12, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Peking University Third Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 12, 2020